Iovance Biotherapeutics (IOVA) said Monday that it has received clearance from the US Food and Drug Administration for its investigational new drug application for a phase 1/2 basket trial of IOV-5001 targeting solid tumors.
The trial will start enrolling patients in H2 to evaluate a one-time IOV-5001 regimen without IL-2 in advanced colorectal, triple-negative and estrogen receptor-low breast cancers, along with other solid tumors, Iovance Biotherapeutics said.
IOV-5001 is designed to improve on an earlier IL-12 tumor infiltrating lymphocyte therapy that showed a 63% objective response rate, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments